Advisors Asset Management Inc. Sells 11,286 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advisors Asset Management Inc. reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 166,047 shares of the biopharmaceutical company's stock after selling 11,286 shares during the quarter. Advisors Asset Management Inc. owned approximately 0.14% of Catalyst Pharmaceuticals worth $3,465,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of CPRX. Victory Capital Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 5.8% in the third quarter. Victory Capital Management Inc. now owns 291,505 shares of the biopharmaceutical company's stock valued at $5,795,000 after purchasing an additional 15,996 shares during the last quarter. Natixis Advisors LLC grew its position in Catalyst Pharmaceuticals by 37.7% in the 3rd quarter. Natixis Advisors LLC now owns 45,637 shares of the biopharmaceutical company's stock worth $907,000 after purchasing an additional 12,491 shares in the last quarter. Quest Partners LLC increased its stake in Catalyst Pharmaceuticals by 36,146.6% in the 3rd quarter. Quest Partners LLC now owns 37,334 shares of the biopharmaceutical company's stock valued at $742,000 after buying an additional 37,231 shares during the last quarter. Segall Bryant & Hamill LLC bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $808,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth approximately $200,000. 79.22% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other news, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Performance

CPRX stock traded down $0.02 during midday trading on Tuesday, reaching $25.72. 1,742,545 shares of the company's stock traded hands, compared to its average volume of 1,063,389. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16. The company has a 50-day moving average price of $22.46 and a two-hundred day moving average price of $21.67. The firm has a market capitalization of $3.12 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Bank of America restated a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Stephens reaffirmed an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.